Literature DB >> 10749586

CRP, TNF-alpha, IL-1ra, IL-6, IL-8 and IL-10 in blood serum of colorectal cancer patients.

J Kamińska1, M M Kowalska, M P Nowacki, M G Chwaliński, A Rysińska, M Fuksiewicz.   

Abstract

Blood serum cytokines: TNFalpha, IL-1ra, IL-6, IL-8, IL-10 as well as CRP were investigated in patients with colorectal cancer, prior treatment and 1, 10 and 42 days after surgery. There was an increase of the levels of CRP, IL-6 and IL-10 in most patients 24 hours after surgery. The levels of IL-1ra were elevated in patients in stage C and in several patients in stage B of the disease and there was a decrease of circulating TNFalpha in stage B patients. On day 10 and 42 after surgery, the levels of cytokines followed various patterns.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10749586     DOI： 10.1007/bf03032656

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN： 1219-4956            Impact factor:   3.201


  10 in total

Review 1.  C-reactive protein: a critical review.

Authors:  B Young; M Gleeson; A W Cripps
Journal:  Pathology       Date:  1991-04       Impact factor: 5.306

2.  Prognostic variables in large bowel cancer.

Authors:  J R Jass
Journal:  J Clin Pathol       Date:  1989-09       Impact factor: 3.411

3.  Association between preoperative acute phase response and postoperative complications.

Authors:  W Haupt; W Hohenberger; R Mueller; P Klein; N V Christou
Journal:  Eur J Surg       Date:  1997-01

4.  In vivo determinations of labelling index of metastatic colorectal carcinoma and normal colonic mucosa using intravenous infusions of bromodeoxyuridine.

Authors:  S Khan; A Raza; N Petrelli; A Mittleman
Journal:  J Surg Oncol       Date:  1988-10       Impact factor: 3.454

5.  Preoperative and postoperative cytokines in patients with cancer.

Authors:  H Nakazaki
Journal:  Cancer       Date:  1992-08-01       Impact factor: 6.860

6.  A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery.

Authors:  D C McMillan; H A Wotherspoon; K C Fearon; C Sturgeon; T G Cooke; C S McArdle
Journal:  Am J Surg       Date:  1995-10       Impact factor: 2.565

7.  Postoperative wound infection. A poor prognostic sign for patients with head and neck cancer.

Authors:  J R Grandis; C H Snyderman; J T Johnson; V L Yu; F D'Amico
Journal:  Cancer       Date:  1992-10-15       Impact factor: 6.860

8.  Inhibitory effects of interleukin 6 on immunity. Possible implications in burn patients.

Authors:  D H Zhou; A M Munster; R A Winchurch
Journal:  Arch Surg       Date:  1992-01

9.  Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma.

Authors:  E Tisi; P Lissoni; M Angeli; C Arrigoni; E Corno; E Cassina; D Ballabio; C Benenti; S Barni; G Tancini
Journal:  Cancer       Date:  1992-05-15       Impact factor: 6.860

10.  Blood cytokine levels rise even after minor surgical trauma.

Authors:  I Grzelak; W L Olszewski; M Zaleska; M Durlik; B Lagiewska; M Muszynski; W Rowinski
Journal:  J Clin Immunol       Date:  1996-05       Impact factor: 8.317
  10 in total
  16 in total

1.  The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis.

Authors:  Maryse Dagenais; Jeremy Dupaul-Chicoine; Todd Douglas; Claudia Champagne; Alexandre Morizot; Maya Saleh
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

2.  Flurbiprofen axetil reduces postoperative sufentanil consumption and enhances postoperative analgesic effects in patients with colorectal cancer surgery.

Authors:  Xue Lin; Ruiqin Zhang; Jingchun Xing; Xiaocui Gao; Pan Chang; Wenzhi Li
Journal:  Int J Clin Exp Med       Date:  2014-12-15

3.  Clinical utility of serum Interleukin-1 receptor antagonist levels as a diagnostic and prognostic assay in surgical patients.

Authors:  Shailendra Kapoor
Journal:  Langenbecks Arch Surg       Date:  2008-09-30       Impact factor: 3.445

4.  Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications.

Authors:  Nikolaos I Nikiteas; Nikolaos Tzanakis; Maria Gazouli; George Rallis; Kessaris Daniilidis; George Theodoropoulos; Alkiviadis Kostakis; George Peros
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

5.  Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients.

Authors:  E-M Reitter; C Ay; A Kaider; R Pirker; C Zielinski; G Zlabinger; I Pabinger
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

Review 6.  Why not treat human cancer with interleukin-1 blockade?

Authors:  Charles A Dinarello
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

Review 7.  Serum interleukin-6 levels in colorectal cancer patients--a summary of published results.

Authors:  Heike Knüpfer; Rainer Preiss
Journal:  Int J Colorectal Dis       Date:  2009-11-07       Impact factor: 2.571

8.  Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients.

Authors:  Magdalena Groblewska; Barbara Mroczko; Mariusz Gryko; Anna Pryczynicz; Katarzyna Guzińska-Ustymowicz; Bogusław Kędra; Andrzej Kemona; Maciej Szmitkowski
Journal:  Tumour Biol       Date:  2014-01-07

9.  Progressive increase of matrix metalloprotease-9 and interleukin-8 serum levels during carcinogenic process in human colorectal tract.

Authors:  Fiorella Biasi; Tina Guina; Marco Maina; Mario Nano; Alessandro Falcone; Emiliano Aroasio; Giorgio Maria Saracco; Mauro Papotti; Gabriella Leonarduzzi; Giuseppe Poli
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

10.  Recovery of immunological homeostasis positively correlates both with early stages of right-colorectal cancer and laparoscopic surgery.

Authors:  Mario Ferri; Simone Rossi Del Monte; Gerardo Salerno; Tommaso Bocchetti; Stefano Angeletti; Florence Malisan; Patrizia Cardelli; Vincenzo Ziparo; Maria Rosaria Torrisi; Vincenzo Visco
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.